SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 1,1999
VidaMed, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-26082 77-0314454
(Commission File Number) (IRS Employer Identification No.)
46107 Landing, Fremont, California 94538
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 492-
4900
Not Applicable
(Former name or former address, if changed since last report.)
<PAGE>
INFORMATION TO BE INCLUDED IN THE REPORT
Item 5. Other Events
Transfer of Listing to Nasdaq SmallCap Market
On December 1, 1999, the registrant received notification from
the Nasdaq-Amex Market Group that effective December 3, 1999,
the listing of registrant's common stock would be moved from the
Nasdaq National Market to the Nasdaq SmallCap Market. The
change in listing follows the November 4, 1999, hearing
conducted by Nasdaq regarding registrant's ability to satisfy
the continued listing requirements of the National Market.
The registrant disclosed Nasdaq's action in a press release
dated December 1, 1999, a copy of which is attached hereto as
Exhibit 99.1.
Item 7 Financial Statements, Pro Forma Financial Information
and Exhibits
99.1 Registrant's Press Release dated December 1, 1999.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly
authorized.
VIDAMED, INC.
(Registrant)
_________________________________
Date: December 8,1999 By /s/ John F. Howe
John F. Howe
Chief Financial Officer
Exhibit 99.1
Thursday December 2, 4:18 pm Eastern Time
Company Press Release
VidaMed Stock to Trade On Nasdaq SmallCap Market
FREMONT, Calif.--(BW HEALTHWIRE)--Dec. 2, 1999--VidaMed, Inc.
(NASDAQ NM:VIDA - news) today announced that it has been
informed by Nasdaq-Amex Market Group that shares of the
Company's common stock, currently traded on the National Market,
will be traded on the
SmallCap Market effective at the beginning of trading on Friday,
December 3,1999.
The Company said that the transfer of VidaMed's listing from the
National Market to the SmallCap Market follows a November 4,
1999, hearing conducted by Nasdaq regarding the
Company's compliance with the continued listing requirements of
the National Market.
Following this move, shares of the Company's common stock will
continue to trade under the ticker symbol VIDA. The Company
believes that the move to the SmallCap Market will not adversely
affect the liquidity of the Company's common stock or the
Company's operations or business plans.
VidaMed designs, develops and markets technologically and
clinically advanced cost-effective systems for the treatment of
urological conditions. The Company's primary product, the
VidaMed TUNA System, offers a minimally invasive treatment of
symptoms associated with benign prostatic hyperplasia, or
enlarged prostate. For investor information about VidaMed,
please call 888-301-2498 or visit VidaMed's Web site at
www.vidamed.com.
This news release contains forward-looking information about the
effect of the transfer of the Company's listing from the
National Market to the SmallCap Market. Actual results may vary
significantly from those anticipated in such forward-looking
statements due to risks and uncertainties, including investor
and market perception of the effect of the transfer and other
risks, including those set forth in the Company's annual,
quarterly and other reports filed from time to time with the
United States Securities and Exchange Commission. The Company's
actual results may differ significantly from the results
anticipated by the forward-looking statements as a result of
these or other factors.
Contact:
Company Contact
VidaMed, Inc.
Randy Lindholm, President & CEO
510/492-4925
John Howe, Chief Financial Officer
510/492-4900
www.vidamed.com
or
Investor Contact
Lippert Heilshorn & Associates
Bruce Voss ([email protected])
310/575-4848
Kim Sutton Golodetz ([email protected])
212/838-3777
or
Media Contact
Elissa Grabowski ([email protected])
212/838-3777
www.lhai.com
